Safety and Effectiveness of Oral Deferiprone (GPO-L-ONE®) in Iron-Overload Children Patient with Thalassemia at Queen Sirikit National Institute of Child Health

Sipornswan P, Pongtanakul B, Viprakrasit V.Prospective clinical evaluation for serious adverse events and complications due to deferiprone (L-1) in pediatric patients. Journal of Hematol & Trandfudion Midicine 2008:33.

Ceci A, Baiardi P, Catapano M, Felisi M, Cianciulli P, De Sanctis V, et al. Rick factors for death in patients with beta-thalassemia major: results of a case-control study.Haematologica 2006; 91:1420-1.

Viprakrasit V. Clinical practice guidline for deferiprone in patients with iron overload: The GovernmentPharmaceutical Organization (GPO) of Thailand. Bangkok; 2009.

DRUGDEX® Evaluations Deferiprone. In: DRUGDEX® System. MICROMEDEX Inc., Greenwood Village, Colorado (Edition expires [unknwn]).

Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89:739-61.

Pootrakul P, Sirankapracha P, Sankote J, Kachintorn U, Mauugsub W, Sriphen K, et al. Clinical trail of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol2003; 122:305-10.

Viprakrasit V, Nuchprayoon I, Chuansumrit A, Torcharus K, Pongtanakul B, Laothamatas J, et al. Deferiprone (GPO-L-ONE®) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Am J Hematolo 2013; 251-60.